Sunday, 03 August 2014 14:38

Anticoagulation news items. Week commencing 28th July 2014

Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation vs. Anticoagulation Alone to Treat Lower-Extremity Proximal Deep Vein Thrombosis

JAMA Internal Medicine

Among 90,618 patients hospitalised for DVT, 3649 underwent catheter-directed thrombolysis (CDT). No difference was found in mortality between CDT and anticoagulation groups (1.2% vs. 0.9%; OR, 1.40; 95% CI, 0.88-2.25; p=0.15).but more adverse events noted in the CDT group.

 

Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores

British Medical Journal
The QBleed risk algorithms were found to provide valid measures of absolute upper gastrointestinal and intracranial bleed risk in new users of anticoagulants (versus non-users), and were validated by a separate validation cohort, with some advantages over other scoring methods.

 

Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator: A Review of Natural History and Treatment

JAMA Neurology
This article reviews the definitions and epidemiologic characteristics of symptomatic intracerebral haemorrhage, with a focus on the rationale and options for treatment.

 

Revised SPC: Eliquis (apixaban) 2.5mg and 5 mg film-coated tablets

electronic Medicines Compendium
Apixban is now also licensed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services